Table 3.
Ability of Change in LS to Predict Hepatic Decompensation (Adjusted)
| Variable | HR (95% Cl) | P Value |
|---|---|---|
| Model 1 | ||
| LS at baseline | 1.54 (1.41–1.94) | <.0001 |
| LS >Δ0.34 kPa/y | 4.32 (1.38–13.56) | .01 |
| Model 2 | ||
| LS >4.32 kPa at baseline | 34.32 (9.37–125.77) | <.0001 |
| LS >Δ0.34 kPa/y | 3.43 (1.24–9.46) | .02 |
| Model 3 | ||
| Features of portal hypertensiona | 9.33 (3.13–27.79) | <.0001 |
| LS >Δ0.34 kPa/y | 14.76 (5.34–40.80) | <.0001 |
| Model 4 | ||
| APRI | 1.48 (1.24–1.77) | <.0001 |
| LS >Δ0.34 kPa/y | 12.36 (4.79–31.93) | <.0001 |
| Model 5 | ||
| Total bilirubin | 1.21 (1.11–1.32) | <.0001 |
| LS >Δ0.34 kPa/y | 11.23 (4.32–29.21) | <.0001 |
| Model 6 | ||
| Mayo PSC risk score | 2.80 (1.78–4.40) | <.0001 |
| LS >Δ0.34 kPa/y | 4.56 (1.50–13.85) | <.001 |
| Model 7 | ||
| PREsTo | 1.04 (1.02–1.06) | <.0001 |
| LS >Δ0.34 kPa/y | 8.49 (3.12–23.09) | <.0001 |
APRI, aspartate aminotransferase-to-platelet ratio index; Cl, confidence interval; HR, hazard ratio; LS, liver stiffness; PREsTo, primary sclerosing cholangitis risk estimate tool; PSC, primary sclerosing cholangitis.
a
Defined by presence of any of the following: splenomegaly, varices or other collaterals or thrombocytopenia (platelets <150 × 109/L).